Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

False Claims Act suit alleging that medical practices engaged in a scheme to overbill Medicare for Amgen Inc. drugs is now dismissed, a New York federal district court said.

Shares of Amgen Inc. AMGN slumped 0.73% to $332.80 Tuesday, on what proved to be an all-around mixed trading session for the ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

An academic partnership to improve diversity in clinical trials has drafted its first industry team members. | An academic ...

In a report released today, Michael Yee from Jefferies assigned a Buy rating to Amgen (AMGN – Research Report), with a price target of ...

We came across a bullish thesis on Amgen Inc. (AMGN) on Disruptive analytics’ Substack by Magnus Ofstad. In this article we will summarize the bulls’ thesis on AMGN. AMGN Technologies ...

GOLF fans were left in shock this afternoon as Rasmus Hojgaard earned the 2024 Amgen Irish Open title. But it was heartbreak ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $380.00. The ...

Amgen (AMGN) ended the recent trading session at $332.80, demonstrating a -0.73% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.03%.

Rory McIlroy is on familiar soil. Eleven days after a tie for ninth in the Tour Championship, McIlroy fired a first-round 68 ...